• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国冠状动脉疾病的医疗费用。

Medical costs of coronary artery disease in the United States.

作者信息

Wittels E H, Hay J W, Gotto A M

机构信息

Department of Internal Medicine, Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030.

出版信息

Am J Cardiol. 1990 Feb 15;65(7):432-40. doi: 10.1016/0002-9149(90)90806-c.

DOI:10.1016/0002-9149(90)90806-c
PMID:2305682
Abstract

A model has been developed to determine the cost of coronary artery disease (CAD) based on the 5 primary events identified in the Framingham Study: acute myocardial infarction, angina pectoris, unstable angina pectoris, sudden death and nonsudden death. The costs for diagnostic and therapeutic service for patients with CAD were linked to medical decision algorithms outlining the diagnosis and management of patients with CAD. Because CAD is a changing illness not represented by a single event, the algorithm tracked patients for 5 years after the time of diagnosis, or until death, to develop average cost estimates. The estimated 5-year costs (in 1986 United States dollars) of the 5 CAD events were: acute myocardial infarction $51,211, angina pectoris $24,980, unstable angina pectoris $40,581, sudden death $9,078 and nonsudden death $19,697. The costs of major CAD surgical procedures were also calculated because of their impact on health care costs for patients with CAD. These include: coronary artery bypass surgery per case over 5 years $32,465, and angioplasty per case over 5 years $26,916. The high cost of CAD reflects the improved technology and more effective and expensive therapies now available.

摘要

基于弗明汉姆研究中确定的5种主要事件,已经开发出一种模型来确定冠状动脉疾病(CAD)的成本,这5种主要事件为:急性心肌梗死、心绞痛、不稳定型心绞痛、猝死和非猝死。CAD患者的诊断和治疗服务成本与概述CAD患者诊断和管理的医学决策算法相关联。由于CAD是一种并非由单一事件所代表的不断变化的疾病,该算法在诊断后对患者进行了5年的跟踪,直至患者死亡,以得出平均成本估算。这5种CAD事件的5年成本估算(以1986年美元计)分别为:急性心肌梗死51,211美元、心绞痛24,980美元、不稳定型心绞痛40,581美元、猝死9,078美元和非猝死19,697美元。由于主要CAD外科手术对CAD患者的医疗保健成本有影响,因此也计算了其成本。这些成本包括:每例冠状动脉搭桥手术5年的成本为32,465美元,每例血管成形术5年的成本为26,916美元。CAD的高成本反映了目前可用的技术改进以及更有效且更昂贵的治疗方法。

相似文献

1
Medical costs of coronary artery disease in the United States.美国冠状动脉疾病的医疗费用。
Am J Cardiol. 1990 Feb 15;65(7):432-40. doi: 10.1016/0002-9149(90)90806-c.
2
Direct medical costs of coronary artery disease in the United States.美国冠状动脉疾病的直接医疗费用。
Am J Cardiol. 1998 May 1;81(9):1110-5. doi: 10.1016/s0002-9149(98)00136-2.
3
Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis.女性疑似冠状动脉疾病的诊断:一项成本效益分析。
Am Heart J. 1999 Jun;137(6):1019-27. doi: 10.1016/s0002-8703(99)70357-1.
4
Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina.RITA-1试验的长期结果:冠状动脉血管成形术与冠状动脉旁路移植术的临床及成本比较。心绞痛随机干预治疗。
Lancet. 1998 Oct 31;352(9138):1419-25. doi: 10.1016/s0140-6736(98)03358-3.
5
Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions.测量血流储备分数以指导冠状动脉介入治疗的成本效益
Am Heart J. 2003 May;145(5):882-7. doi: 10.1016/S0002-8703(03)00072-3.
6
Comparison of costs of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG) for patients with angina pectoris.
Eur Heart J. 1991 Feb;12(2):288. doi: 10.1093/oxfordjournals.eurheartj.a059885.
7
API expert consensus document on management of ischemic heart disease.缺血性心脏病管理的API专家共识文件
J Assoc Physicians India. 2006 Jun;54:469-80.
8
Comparison of costs of percutaneous transluminal coronary angioplasty and coronary bypass surgery for patients with angina pectoris.经皮腔内冠状动脉成形术与冠状动脉搭桥手术治疗心绞痛患者的成本比较。
Eur Heart J. 1990 Aug;11(8):765-71. doi: 10.1093/oxfordjournals.eurheartj.a059792.
9
Implications of cost in treatment selection for patients with coronary heart disease.成本对冠心病患者治疗选择的影响。
Ann Thorac Surg. 1996 Feb;61(2 Suppl):S12-5; discussion S33-4. doi: 10.1016/0003-4975(95)01077-7.
10
Is medical treatment for angina the most cost-effective option?
Eur Heart J. 1997 May;18 Suppl B:B35-42. doi: 10.1093/eurheartj/18.suppl_b.35.

引用本文的文献

1
3D-Printed Polymeric Biomaterials for Health Applications.用于健康应用的3D打印聚合物生物材料。
Adv Healthc Mater. 2025 Jan;14(1):e2402571. doi: 10.1002/adhm.202402571. Epub 2024 Nov 5.
2
Reappraising the public health benefits conferred by environmental policy: Considerations for an aging society.重新评估环境政策带来的公共卫生效益:老龄化社会的考虑因素。
J Am Geriatr Soc. 2023 Apr;71(4):1291-1299. doi: 10.1111/jgs.18219. Epub 2022 Dec 31.
3
Effects of Increasing Aridity on Ambient Dust and Public Health in the U.S. Southwest Under Climate Change.
气候变化下美国西南部干旱加剧对大气尘埃及公众健康的影响
Geohealth. 2019;3(5):127-144. doi: 10.1029/2019GH000187.
4
A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.基于心血管结局的降脂疗法成本效益分析的系统评价
Pharmacoeconomics. 2017 Mar;35(3):297-318. doi: 10.1007/s40273-016-0464-2.
5
Cost-effectiveness of new cardiac and vascular rehabilitation strategies for patients with coronary artery disease.冠心病患者新型心脏和血管康复策略的成本效益
PLoS One. 2008;3(12):e3883. doi: 10.1371/journal.pone.0003883. Epub 2008 Dec 9.
6
Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.在冠心病一级预防中治疗低高密度脂蛋白胆固醇的成本效益
Pharmacoeconomics. 2005;23(2):133-41. doi: 10.2165/00019053-200523020-00005.
7
Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.用于冠状动脉疾病一级和二级预防的降脂药物的药物经济学
Pharmacoeconomics. 1999 Jan;15(1):47-74. doi: 10.2165/00019053-199915010-00004.
8
Pharmacoeconomics of genetically engineered drugs.基因工程药物的药物经济学
Pharmacoeconomics. 1992 Jan;1(1):45-53. doi: 10.2165/00019053-199201010-00009.
9
Costs of illness in cost-effectiveness analysis. A review of the methodology.成本效益分析中的疾病成本。方法学综述。
Pharmacoeconomics. 1994 Dec;6(6):536-52. doi: 10.2165/00019053-199406060-00007.
10
Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents.
Pharmacoeconomics. 1992 Oct;2(4):270-8. doi: 10.2165/00019053-199202040-00003.